Oncternal Therapeutics, Inc. (ONCT) has a consensus analyst rating of Buy, based on 7 analysts covering the stock. Of those, 4 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for ONCT is $28.00, representing a +5,217.1% upside from the current price of $0.5266. Price targets range from a low of $28.00 to a high of $28.00.
